A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin

PURPOSE: This analysis determined the incidence of serious rhabdomyolysis events reported during trabectedin treatment since the first phase I clinical trial in April 1996 up to September 2010. METHODS: Search was done in the Yondelis(®) Pharmacovigilance and Clinical Trials databases using a list o...

Descripción completa

Detalles Bibliográficos
Autores principales: Grosso, Federica, D’Incalci, Maurizio, Cartoafa, Mirela, Nieto, Antonio, Fernández-Teruel, Carlos, Alfaro, Vicente, Lardelli, Pilar, Roy, Elena, Gómez, Javier, Kahatt, Carmen, Soto-Matos, Arturo, Judson, Ian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362698/
https://www.ncbi.nlm.nih.gov/pubmed/22484722
http://dx.doi.org/10.1007/s00280-012-1864-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362698/
https://www.ncbi.nlm.nih.gov/pubmed/22484722
http://dx.doi.org/10.1007/s00280-012-1864-4

Ejemplares similares